Pharmacoeconomic evaluation of ipragliflozin in combination with metformin in comparison with other regimens of therapy for type 2 diabetes mellitus

Ipragliflozin is a selective sodium-glucose cotransporter 2 (SGLT2) inhibitor that reduce plasma glucose concentrations by inhibiting glucose reabsorption by the kidney through inhibiting SGLT2 sodium-glucose cotransporter and induce glycosuria. SGLT2 inhibitors are a new class of glucose lowering drugs most recently approved for treatment of type 2 diabetes mellitus (T2DM). Unlike other antidiabetic agents, SGLT2 inhibitors improve glycemic control (by HbA1c) and provide multiple additional benefits, including decreased body weight, blood pressure, and other multiple pleiotropic effects. The completed clinical trials and real world data have provided evidence that including of SGLT2 inhibitors in the treatment of T2DM has benefits of reduction of cardiovascular and renal outcomes.
Goal. The aim of the study was to conduct a clinical and economic examination of ipragliflozin in comparison with other regimens of glucose-lowering therapy with other SGLT2 inhibitors.
Methods. In carrying out the pharmacoeconomic analysis itself, a cost-effectiveness analysis (CEA) was applied with the calculation of the corresponding cost-effectiveness ratio (CER), incremental cost-effectiveness ratio (ICER) according to the formula, as well as an a «budget impact analysis». Multiple one-way sensitivity analysis, check the robustness of the results of the main scenario results to changes in key parameters such as the cost of drugs and complications of diabetes. The time horizon for analyzing the dynamics of economic consequences when using ipragliflozin as a glucose-lowering therapy for T2DM was 5 years.
Results. The weighted average cost per patient per year when using the ipragliflozin treatment strategy is 31,182 rubles. The costs of the empagliflozin strategy are 61,291 rubles per patient. In the case of using dapagliflozin, the weighted average costs are 30,032 rubles per patient per year, the total direct medical costs for the current drug therapy option, calculated on the initial number of target practice in 72,143 patients with type 2 diabetes, amounted to 3,068,642,442 rubles. Analysis of the trend of changes in weighted average costs showed that the broader use of ipragliflozin for the treatment of T2DM in the target population leads to reducing in diabetes related direct medical costs by 6.7 %, while the total economic effect of ipragliflozin introduction over five years will be 501,539,327 rubles.
Conclusions. Use of ipragliflozin + metformin in T2DM treatment is a cost-effective strategy compared to empagliflozin + metformin. The combination of ipragliflozin with metformin versus dapagliflozin + metformin is economically feasible in terms of cost-effectiveness.

1. IDF Diabetes Atlas 9th edition 2019 [Internet]. Diabetesatlas.org. 2020 [cited 16 December 2020]. Available from: https://www.diabetesatlas.org/

2. https://www.nature.com/articles/s41598-020-71908-9

3. https://www.endocrincentr.ru/sites/default/files/specialists/science/clinic-recomendations/saharnyy_diabet_2_tipa_u_vzroslyh.pdf

4. Tsuyoshi Ohkura. Ipragliflozin: A novel sodium-glucose cotransporter 2 inhibitor developed in Japan. World J Diabetes. Feb 15, 2015;6(1):136-144. DOI: 10.4239/wjd.v6.i1.136.

5. https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=fb10db64-4cd6-4bb1-8549-70f5a51bae6d&t=

6. Quality of life in type 2 diabetic patients is affected by complications but not by intensive policies to improve blood glucose or blood pressure control (UKPDS 37). U.K. Prospective Diabetes Study Group. Diabetes Care. 1999;22(7):1125-36. DOI: 10.2337/diacare.22.7.1125.

7. Hex N, Bartlett C, Wright D et al. Estimating the current and future costs of Type 1 and Type 2 diabetes in the UK, including direct health costs and indirect societal and productivity costs. Diabet Med. 2012;29(7):855- 62. DOI: 10.1111/j.1464-5491.2012.03698.x

8. Jönsson B. Revealing the cost of Type II diabetes in Europe. Diabetologia. 2002;45(S1):S5-S12. DOI: 10.1007/s00125-002-0858-x.

9. Kolbin AS, Mosikyan AA, Kurylev AA et al. Economic analysis of Lixisenatide in Diabetes Mellitus Type 2. Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice. 2015;(4):53-63. (In Russ.).

10. Колбин А.С., Хмельницкий О.К., Курылев А.А. и др. Первый в России опыт построения симуляционной модели исходов сахарного диабета 2 типа с дискретированным моделированием событий. Клиникоэкономическая экспертиза // Фармакоэкономика. 2013;6(2):24-31. [Kolbin AS, Khmelnitskiy OK, Kurylev AA et al. First russian type 2 diabetes mellitus simulation model with discreet events modeling. Healtheconomic analysis. Pharmacoeconom. 2013;6(2):24-31. (In Russ).]

11. Saenz A, Fernandez-Esteban I, Mataix A et al. Metformin monotherapy for type 2 diabetes mellitus. Cochrane Database Syst Rev. 2005(3):CD002966.

12. Domecq JP. Clinical review: Drugs commonly associated with weight change: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2015 Feb;100(2):363-70. DOI: 10.1210/jc.2014-3421.

13. J Ma et al. Comparison of Metformin and Repaglinide Monotherapy in the Treatment of New Onset Type 2 Diabetes Mellitus in China. J Diabetes Res. 2014;2014:294017. DOI: 10.1155/2014/294017.

14. HJ Lambers Heerspink et al. Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes. Diabetes Obes Metab. 2013 Sep;15(9):853-62. DOI: 10.1111/dom.12127.

15. Roden M et al. Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, doubleblind, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol. 2013 Nov;1(3):208-19. DOI: 10.1016/S2213-8587(13)70084-6.

16. Tsurutani Y et al. Comparative study of the effects of ipragliflozin and sitagliptin on multiple metabolic variables in Japanese patients with type 2 diabetes: A multicentre, randomized, prospective, open-label, activecontrolled study. Diabetes Obes Metab. 2018 Nov;20(11):2675-2679. DOI: 10.1111/dom.13421.

17. Nakamura I et al. Safety and efficacy of ipragliflozin in Japanese patients with type 2 diabetes in real-world clinical practice: interim results of the STELLA-LONG TERM post-marketing surveillance study. Expert Opin Pharmacother. 2018 Feb;19(3):189-201. DOI: 10.1080/14656566.2017.

18. Clarke PM, Gray AM, Briggs A et al. A model to estimate the lifetime health outcomes of patients with type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS no. 68). Diabetologia. 2004;47(10):1747-59. DOI: 10.1007/s00125-004-1527-z.

19. Mueller E, Maxion-Bergemann S, Gultyaev D et al. Development and validation of the Economic Assessment of Glycemic Control and Long-Term Effects of diabetes (EAGLE) model. Diabetes Technol Ther. 2006 Apr;8(2):219-36. DOI: 10.1089/dia.2006.8.219.

20. Bekiari E, Rizava C, Athanasiadou E et al. Systematic review and meta-analysis of vildagliptin for treatment of type 2 diabetes. Endocrine. 2016 Jun;52(3):458-80. DOI: 10.1007/s12020-015-0841-1.

21. Об утверждении отраслевого стандарта «клинико-экономиеские исследования. общие положения»: приказ № 163 Министерства Здравоохранения Российской Федерации от 27.05.2011. [Ob utverzhdenii otraslevogo standarta «kliniko-ekonomieskie issledovaniya. obshchie polozheniya»: Order No. 163 of the Ministry of Health of the Russian Federation of 27.05.2011. (In Russ).]. Доступно по: http://docs.cntd.ru/document/901823470. Ссылка активна на 08.12.2020.

22. Национальный стандарт Российской Федерации. ГОСТ Р 56044- 2014. Оценка медицинских технологий. Общие положения. Утвержден и введен в действие Приказом Федерального агентства по техническому регулированию и метрологии Российской Федерации от 11 июня 2014 г. № 568-ст // [Электронный ресурс]. [National standard of the Russian Federation. GOST R 56044-2014. Evaluation of medical technologies. General provisions. Approved and put into effect by Order of the Federal Agency for Technical Regulation and Metrology of the Russian Federation of June 11, 2014 N 568-st. [Internet]. (In Russ).] Режим доступа: http://docs.cntd.ru/document/1200111499. Ссылка активна на 08.12.2020.

23. Национальный стандарт Российской Федерации. ГОСТ Р 57525-2017. Клинико-экономические исследования. Общие требования. Утвержден и введен в действие Приказом Федерального агентства по техническому регулированию и метрологии от 6 июля 2017 г. N 655-ст // [Электронный ресурс] [National standard of the Russian Federation. GOST R 57525-2017. Clinical and economic research. General requirements. Approved and put into effect by Order of the Federal Agency for Technical Regulation and Metrology of July 6, 2017 N 655-st. [Internet]. (In Russ).] Режим доступа: http://docs.cntd.ru/document/1200146142. Ссылка активна на 08.12.2020.

24. Оценка медицинских технологий, Рекомендации 2013 г. / Под общей редакцией Белоусова Ю.Б. — М.: Издательство ОКИ; 2013. — 40 с. [Evaluation of medical technologies, Recommendations 2013. Ed by Belousov YuB. Moscow: Publishing OKI; 2013. (In Russ).]

25. Jansen JP et al. Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 1. Value Health. 2011 Jun;14(4):417-28. DOI: 10.1016/j.jval.2011.04.002.

26. Bucher HC, Gordon HG, Lauren EG et al. The Results of Direct and Indirect Treatment Comparisons in Meta-Analysis of Randomized Controlled Trials. J Clin Epidemiol. 1997;50(6):683-91. DOI: 10.1016/s0895-4356(97)00049-8.

27. Омельяновский В.В. и др. Методические рекомендации по проведению непрямых сравнений лекарственных препаратов. [Электронный ресурс]. [Omelyanovsky VV et al. Methodological recommendations for conducting indirect comparisons of drugs. [Internet]. (In Russ).] Доступно по: https://clck.ru/ETmwS. Ссылка активна на 08.12.2020.

28. Пахомов Я., Вознесенский Н. Сравнительная клиническая и фармакоэкономическая эффективность ипраглифлозина в терапии сахарного диабета 2 типа в сравнении с дапаглифлозином и эмпаглифлозином. Подговлено Medical advisers group | подразделение ООО Сиарэй Клаб. [Pakhomov Ya, Voznesensky N. Comparative clinical and pharmacoeconomical efficacy of ipragliflozin in the treatment of type 2 diabetes mellitus in comparison with dapagliflozin and empagliflozin. Prepared by Medical advisors group / a division of Siaray Club LLC. (In Russ).].

29. ATC/DDD Index 2015. — http://www.whocc.no/atc_ddd_index/

30. Государственный реестр предельных отпускных цен. [Электронный ресурс]. [State register of marginal selling prices. [Internet]. (In Russ).] Доступно по: http://www.grls.ru Ссылка активна на 08.12.2020.

31. Реестр государственных закупок. [Электронный ресурс]. [Register of public procurement. [Internet]. (In Russ).] Доступно по: http://zakupki.gov.ru Ссылка активна на 08.12.2020.

32. Постановление Правительства России от 10.12.2018 N 1506 «О Программе государственных гарантий бесплатного оказания гражданам медицинской помощи на 2019 год и на плановый период 2020 и 2021 годов». [Resolution of the Government of Russia of 10.12.2018 N 1506 «O Programme gosudarstvennyh garantij besplatnogo okazaniya grazhdanam medicinskoj pomoshchi na 2019 god i na planovyj period 2020 i 2021 godov». (In Russ).]

33. Генеральное тарифное соглашение ОМС, 2019 год [Электронный ресурс]. [General Tariff Agreement of the MHI, 2019. [Internet]. (In Russ).] Доступно по: http://www.spboms.ru Ссылка активна на 08.12.2020.